Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Maple syrup urine disease (MSUD) is an inherited disorder of branched-chain amino acid metabolism presenting with life-threatening cerebral oedema and dysmyelination in affected individuals. Treatment requires life-long dietary restriction and monitoring of branched-chain amino acids to avoid brain injury. Despite careful management, children commonly suffer metabolic decompensation in the context of catabolic stress associated with non-specific illness. The mechanisms underlying this decompensation and brain injury are poorly understood. Using recently developed mouse models of classic and intermediate maple syrup urine disease, we assessed biochemical, behavioural and neuropathological changes that occurred during encephalopathy in these mice. Here, we show that rapid brain leucine accumulation displaces other essential amino acids resulting in neurotransmitter depletion and disruption of normal brain growth and development. A novel approach of administering norleucine to heterozygous mothers of classic maple syrup urine disease pups reduced branched-chain amino acid accumulation in milk as well as blood and brain of these pups to enhance survival. Similarly, norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease. Current findings suggest two converging mechanisms of brain injury in maple syrup urine disease including: (i) neurotransmitter deficiencies and growth restriction associated with branched-chain amino acid accumulation and (ii) energy deprivation through Krebs cycle disruption associated with branched-chain ketoacid accumulation. Both classic and intermediate models appear to be useful to study the mechanism of brain injury and potential treatment strategies for maple syrup urine disease. Norleucine should be further tested as a potential treatment to prevent encephalopathy in children with maple syrup urine disease during catabolic stress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berry, G. T., Kaplan, P. B., Kaye, E. M., Jan, W., Zimmerman, R. A., & Wang, Z. J. (2003) · Neuroradiology · doi:10.1007/s00234-003-0955-7 · Cited by 176
Dysmyelination in the brain of adolescents and young adults with maple syrup urine disease
SCHONBERGER, S. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.01.016 · Cited by 101 · cited 4×
“Similar changes have been reported in non-encephalopathic adolescent and adult patients with MSUD (Schonberger et al., 2004).”
BackgroundResultInfluential
Cited by
Branched-chain amino acids in metabolic signalling and insulin resistance
Lynch, C. J., & Adams, S. H. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.171 · Cited by 1,461
Biosynthesis, production and applications of bacterial cellulose
Lin, S.-P., Loira Calvar, I., Catchmark, J. M., Liu, J.-R., Demirci, A., & Cheng, K.-C. (2013) · Cellulose · doi:10.1007/s10570-013-9994-3 · Cited by 473
Self-citationImpaired Amino Acid Transport at the Blood Brain Barrier Is a Cause of Autism Spectrum Disorder
Tărlungeanu, D. C., Deliu, E., Dotter, C. P., Kara, M., Janiesch, P. C., Scalise, M., Galluccio, M., Tesulov, M., Morelli, E., Sonmez, F. M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.013 · Cited by 367
Mutations in BCKD-kinase Lead to a Potentially Treatable Form of Autism with Epilepsy
Novarino, G., El-Fishawy, P., Kayserili, H., Meguid, N. A., Scott, E. M., Schroth, J., Silhavy, J. L., Kara, M., Khalil, R. O., Ben-Omran, T., et al. (2012) · Science · doi:10.1126/science.1224631 · Cited by 320
Targeting BCAA Catabolism to Treat Obesity-Associated Insulin Resistance
Zhou, M., Shao, J., Wu, C.-Y., Shu, L., Dong, W., Liu, Y., Chen, M., Wynn, R. M., Wang, J., Wang, J., et al. (2019) · Diabetes · doi:10.2337/db18-0927 · Cited by 318
Metadata
- Authors
- Zinnanti, W. J., Lazovic, J., Griffin, K., Skvorak, K. J., Paul, H. S., Homanics, G. E., Bewley, M. C., Cheng, K. C., LaNoue, K. F., & Flanagan, J. M.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-05-21
- Volume
- 132
- Issue
- 4
- Pages
- 903-918
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2168533782
- Cited by
- 157
- References
- 2
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.